Gilead Sciences Inc Drug Patent Portfolio
Gilead Sciences Inc owns 17 orange book drugs protected by 162 US patents with Tybost having the least patent protection, holding only 4 patents. And Stribild with maximum patent protection, holding 35 patents. Given below is the list of Gilead Sciences Inc's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11491169 | Remdesivir treatment methods | 28 Nov, 2041 | Active |
US11903953 | Remdesivir treatment methods | 28 Nov, 2041 | Active |
US11975012 | Remdesivir treatment methods | 28 Nov, 2041 | Active |
US11944611 | Capsid inhibitors for the treatment of HIV | 04 Jun, 2041 | Active |
US11491169 | Remdesivir treatment methods | 28 May, 2041 | Active |
US11903953 | Remdesivir treatment methods | 28 May, 2041 | Active |
US11975012 | Remdesivir treatment methods | 28 May, 2041 | Active |
US10675296 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | 10 Jan, 2039 | Active |
US11266681 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | 10 Jan, 2039 | Active |
US11975017 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | 10 Jan, 2039 | Active |
US11267799 | Solid forms of an HIV capsid inhibitor | 16 Aug, 2038 | Active |
US10675296 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | 10 Jul, 2038 | Active |
US11266681 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | 10 Jul, 2038 | Active |
US11975017 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections | 10 Jul, 2038 | Active |
US11338007 | Combination formulation of three antiviral compounds | 01 Dec, 2037 | Active |
US10071985 | Therapeutic compounds | 17 Aug, 2037 | Active |
US10654827 | Therapeutic compounds | 17 Aug, 2037 | Active |
US10912814 | Combination formulation of three antiviral compounds | 01 Jun, 2037 | Active |
US11338007 | Combination formulation of three antiviral compounds | 01 Jun, 2037 | Active |
US10695361 | Methods for treating arenaviridae and coronaviridae virus infections | 16 Mar, 2037 | Active |
US11007208 | Methods for treating arenaviridae and coronaviridae virus infections | 16 Mar, 2037 | Active |
US11382926 | Methods for treating Arenaviridae and Coronaviridae virus infections | 16 Mar, 2037 | Active |
US10548846 | Therapeutic compositions for treatment of human immunodeficiency virus | 08 Nov, 2036 | Active |
US11744802 | Therapeutic compositions for treatment of human immunodeficiency virus | 08 Nov, 2036 | Active |
US10695361 | Methods for treating arenaviridae and coronaviridae virus infections | 16 Sep, 2036 | Active |
US11007208 | Methods for treating arenaviridae and coronaviridae virus infections | 16 Sep, 2036 | Active |
US11382926 | Methods for treating Arenaviridae and Coronaviridae virus infections | 16 Sep, 2036 | Active |
US9724360 | Methods for treating Filoviridae virus infections | 29 Apr, 2036 | Active |
US9949994 | Methods for treating Filoviridae virus infections | 29 Apr, 2036 | Active |
US9724360 | Methods for treating Filoviridae virus infections | 29 Oct, 2035 | Active |
US9949994 | Methods for treating Filoviridae virus infections | 29 Oct, 2035 | Active |
US10385067 | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate | 19 Jun, 2035 | Active |
US9708342 | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate | 19 Jun, 2035 | Active |
US10086011 | Combination formulation of two antiviral compounds | 30 Jul, 2034 | Active |
US11116783 | Combination formulation of two antiviral compounds | 30 Jul, 2034 | Active |
US11707479 | Combination formulation of two antiviral compounds | 30 Jul, 2034 | Active |
US9757406 | Combination formulation of two antiviral compounds | 30 Jul, 2034 | Active |
US10039779 | Combination formulation of two antiviral compounds | 30 Jul, 2034 | Active |
US9296782 | Inhibitors of hepatitis C virus | 17 Jul, 2034 | Active |
US9951043 | Therapeutic compounds | 28 Feb, 2034 | Active |
US10086011 | Combination formulation of two antiviral compounds | 30 Jan, 2034 | Active |
US11116783 | Combination formulation of two antiviral compounds | 30 Jan, 2034 | Active |
US11707479 | Combination formulation of two antiviral compounds | 30 Jan, 2034 | Active |
US9757406 | Combination formulation of two antiviral compounds | 30 Jan, 2034 | Active |
US10039779 | Combination formulation of two antiviral compounds | 30 Jan, 2034 | Active |
US9216996 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections | 19 Dec, 2033 | Active |
US9732092 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections | 19 Dec, 2033 | Active |
US9469643 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one | 02 Sep, 2033 | Active |
US8575135 | Antiviral compounds | 16 May, 2033 | Active |
US8921341 | Antiviral compounds | 16 May, 2033 | Active |
US8940718 | Antiviral compounds | 16 May, 2033 | Active |
US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent | 06 Apr, 2033 | Active |
US9393256 | Methods for treating HCV | 14 Mar, 2033 | Active |
US10730879 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one | 05 Mar, 2033 | Active |
US8865730 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one | 05 Mar, 2033 | Active |
US8754065 | Tenofovir alafenamide hemifumarate | 15 Feb, 2033 | Active |
US9296769 | Tenofovir alafenamide hemifumarate | 15 Feb, 2033 | Active |
US10857102 | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate | 14 Jan, 2033 | Active |
US8575135 | Antiviral compounds | 16 Nov, 2032 | Active |
US8921341 | Antiviral compounds | 16 Nov, 2032 | Active |
US8940718 | Antiviral compounds | 16 Nov, 2032 | Active |
US9868745 | Antiviral compounds | 16 Nov, 2032 | Active |
US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent | 06 Oct, 2032 | Active |
US10456414 | Methods for treating HCV | 14 Sep, 2032 | Active |
US9393256 | Methods for treating HCV | 14 Sep, 2032 | Active |
US8754065 | Tenofovir alafenamide hemifumarate | 15 Aug, 2032 | Active |
US9296769 | Tenofovir alafenamide hemifumarate | 15 Aug, 2032 | Active |
US11492353 | Methods and compounds for treating Paramyxoviridae virus infections | 08 Jun, 2032 | Active |
US10065958 | Methods and compounds for treating Paramyxoviridae virus infections | 16 Mar, 2032 | Active |
US11492353 | Methods and compounds for treating Paramyxoviridae virus infections | 08 Dec, 2031 | Active |
US10065958 | Methods and compounds for treating Paramyxoviridae virus infections | 16 Sep, 2031 | Active |
US8618076 | Nucleoside phosphoramidates | 11 Jun, 2031 | Active |
US9284342 | Nucleoside phosphoramidates | 13 Mar, 2031 | Active |
US8618076 | Nucleoside phosphoramidates | 11 Dec, 2030 | Active |
US8088368 | Antiviral compounds | 12 Nov, 2030 | Active |
US8273341 | Antiviral compounds | 12 Nov, 2030 | Active |
US8822430 | Antiviral compounds | 12 Nov, 2030 | Active |
US8841278 | Antiviral compounds | 12 Nov, 2030 | Active |
US9511056 | Antiviral compounds | 12 Nov, 2030 | Active |
US8633219 | Combination therapy | 30 Oct, 2030 | Active |
US9284342 | Nucleoside phosphoramidates | 13 Sep, 2030 | Active |
US8088368 | Antiviral compounds | 12 May, 2030 | Active |
US8273341 | Antiviral compounds | 12 May, 2030 | Active |
US8822430 | Antiviral compounds | 12 May, 2030 | Active |
US8841278 | Antiviral compounds | 12 May, 2030 | Active |
US9511056 | Antiviral compounds | 12 May, 2030 | Active |
US8633219 | Combination therapy | 30 Apr, 2030 | Active |
US9492449 | Therapies for hematologic malignancies | 11 Mar, 2030 | Active |
US8008264 | 1′-substituted carba-nucleoside analogs for antiviral treatment | 06 Mar, 2030 | Active |
US8148374 | Modulators of pharmacokinetic properties of therapeutics | 03 Mar, 2030 | Active |
US9891239 | Modulators of pharmacokinetic properties of therapeutics | 03 Mar, 2030 | Active |
US8318682 | 1′substituted carba-nucleoside analogs for antiviral treatment | 22 Oct, 2029 | Active |
USRE46762 | 1′-substituted carba-nucleoside analogs for antiviral treatment | 22 Oct, 2029 | Active |
US7964580 | NA | 26 Sep, 2029 | Active |
US8633309 | Nucleoside phosphoramidates | 26 Sep, 2029 | Active |
US8889159 | Compositions and methods for treating hepatitis C virus | 26 Sep, 2029 | Active |
US9549941 | Compositions and methods for treating hepatitis C virus | 26 Sep, 2029 | Active |
US8008264 | 1′-substituted carba-nucleoside analogs for antiviral treatment | 06 Sep, 2029 | Active |
US8148374 | Modulators of pharmacokinetic properties of therapeutics | 03 Sep, 2029 | Active |
US9891239 | Modulators of pharmacokinetic properties of therapeutics | 03 Sep, 2029 | Active |
US8318682 | 1′substituted carba-nucleoside analogs for antiviral treatment | 22 Apr, 2029 | Active |
USRE46762 | 1′-substituted carba-nucleoside analogs for antiviral treatment | 22 Apr, 2029 | Active |
US7964580 | NA | 26 Mar, 2029 | Active |
US8633309 | Nucleoside phosphoramidates | 26 Mar, 2029 | Active |
US8889159 | Compositions and methods for treating hepatitis C virus | 26 Mar, 2029 | Active |
US9549941 | Compositions and methods for treating hepatitis C virus | 26 Mar, 2029 | Active |
US8334270 | NA | 21 Sep, 2028 | Active |
US8580765 | NA | 21 Sep, 2028 | Active |
US8735372 | NA | 21 Sep, 2028 | Active |
US9085573 | NA | 21 Sep, 2028 | Active |
US8334270 | NA | 21 Mar, 2028 | Active |
US8580765 | NA | 21 Mar, 2028 | Active |
US8735372 | NA | 21 Mar, 2028 | Active |
US9085573 | NA | 21 Mar, 2028 | Active |
US8957046 | NA | 21 Mar, 2028 | Active |
US9585906 | NA | 21 Mar, 2028 | Active |
US7635704 | Stable crystal of 4-oxoquinoline compound | 26 Apr, 2027 | Active |
US8981103 | Stable crystal of 4-oxoquinoline compound | 26 Apr, 2027 | Active |
US7176220 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | 27 Feb, 2027 | Active |
US7635704 | Stable crystal of 4-oxoquinoline compound | 26 Oct, 2026 | Active |
US8981103 | Stable crystal of 4-oxoquinoline compound | 26 Oct, 2026 | Active |
US7176220 | 4-oxoquinoline compound and use thereof as pharmaceutical agent | 27 Aug, 2026 | Active |
US8841310 | Combinations of a pyrimidine containing NNRTI with RT inhibitors | 09 Dec, 2025 | Active |
US7390791 | Prodrugs of phosphonate nucleotide analogues | 17 Oct, 2025 | Active |
USRE44638 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | 05 Aug, 2025 | Active |
USRE44599 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta | 21 Jul, 2025 | Active |
US8980901 | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta | 12 May, 2025 | Active |
US9149477 | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | 12 May, 2025 | Active |
US7125879 | HIV inhibiting pyrimidines derivatives | 21 Apr, 2025 | Active |
US7390791 | Prodrugs of phosphonate nucleotide analogues | 17 Apr, 2025 | Active |
US8716264 | Compositions and methods for combination antiviral therapy | 13 Jul, 2024 | Expired |
US8592397 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
US8716264 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
US9457036 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
US9744181 | Compositions and methods for combination antiviral therapy | 13 Jan, 2024 | Expired |
US8080551 | HIV inhibiting pyrimidines derivatives | 11 Apr, 2023 | Expired |
US8101629 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile | 09 Aug, 2022 | Expired |
US7803788 | Prodrugs of phosphonate nucoleotide analogues | 02 Feb, 2022 | Expired |
US7800788 | Upright image processing apparatus with pivotable image reading portion | 02 Feb, 2022 | Expired |
US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers | 09 Sep, 2021 | Expired |
US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 04 May, 2021 | Expired |
US6800620 | Inhibitors of human phosphatidylinositol 3-kinase delta | 24 Apr, 2021 | Expired |
US6949535 | Inhibitors of human phosphatidyl-inositol 3-kinase delta | 24 Apr, 2021 | Expired |
US8138195 | Inhibitors of human phosphatidylinositol 3-kinase delta | 24 Apr, 2021 | Expired |
US8492389 | Inhibitors of human phosphatidylinositol 3-kinase delta | 24 Apr, 2021 | Expired |
US8637533 | Inhibitors of human phosphatidylinositol 3-kinase delta | 24 Apr, 2021 | Expired |
US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers | 09 Mar, 2021 | Expired |
US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents | 26 Feb, 2021 | Expired |
US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 04 Nov, 2020 | Expired |
US7067522 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents | 20 Dec, 2019 | Expired |
US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability | 25 Jan, 2018 | Expired |
US5935946 | Nucleotide analog composition and synthesis method | 25 Jan, 2018 | Expired |
US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jan, 2018 | Expired |
US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jan, 2018 | Expired |
US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 02 Jan, 2018 | Expired |
US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability | 25 Jul, 2017 | Expired |
US5935946 | Nucleotide analog composition and synthesis method | 25 Jul, 2017 | Expired |
US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jul, 2017 | Expired |
US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability | 25 Jul, 2017 | Expired |
US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | 02 Jul, 2017 | Expired |
US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds | 29 Mar, 2016 | Expired |
US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds | 29 Sep, 2015 | Expired |
Latest Legal Activities on Gilead Sciences Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Gilead Sciences Inc.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jul, 2024 | US9549941 |
Electronic Review
Critical
| 07 Jun, 2024 | US11944611 |
Payment of Maintenance Fee, 12th Year, Large Entity | 05 Jun, 2024 | US8334270 |
Payment of Maintenance Fee, 12th Year, Large Entity | 05 Jun, 2024 | US8334270 |
Petition Entered | 30 May, 2024 | US11944611 |
Payment of Maintenance Fee, 8th Year, Large Entity | 22 May, 2024 | US9511056 |
Payment of Maintenance Fee, 4th Year, Large Entity | 22 May, 2024 | US10857102 |
Payment of Maintenance Fee, 12th Year, Large Entity | 15 May, 2024 | US8318682 |
Second letter to regulating agency to determine regulatory review period | 10 May, 2024 | US9951043 |
Payment of Maintenance Fee, 8th Year, Large Entity | 01 May, 2024 | US9492449 |
Expire Patent
Critical
| 22 Apr, 2024 | US8138195 |
Payment of Maintenance Fee, 8th Year, Large Entity | 03 Apr, 2024 | US9469643 |
Recordation of Patent eGrant | 02 Apr, 2024 | US11944611 |
Mail Patent eGrant Notification | 02 Apr, 2024 | US11944611 |
Patent eGrant Notification | 02 Apr, 2024 | US11944611 |
Gilead Sciences Inc's Drug Patent Litigations
Gilead Sciences Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 05, 2001, against patent number US6642245. The petitioner , challenged the validity of this patent, with DIONNE as the respondent. Click below to track the latest information on how companies are challenging Gilead Sciences Inc's patents.
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
US8889159 | December, 2017 |
Terminated-Denied
(19 Jul, 2018)
| Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. |
US9393256 | December, 2017 |
Terminated-Denied
(20 Jun, 2018)
| Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. |
US8735372 | November, 2017 |
Institution Denied
(13 Jun, 2018)
| Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
US8633309 | October, 2017 |
Institution Denied
(24 May, 2018)
| Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
US9284342 | November, 2017 |
Institution Denied
(24 May, 2018)
| Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
US8334270 | October, 2017 |
Institution Denied
(21 May, 2018)
| Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
US7964580 | October, 2017 |
Institution Denied
(04 May, 2018)
| Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
US9891239 | August, 2013 |
Decision
(20 Jul, 2016)
| Manoj C. Desai et al | |
US5935946 | June, 2014 |
Terminated-Denied
(17 Dec, 2014)
| Gilead Sciences, Inc. | MYLAN PHARMACEUTICALS INC. |
US5922695 | June, 2014 |
Terminated-Denied
(09 Dec, 2014)
| Gilead Sciences, Inc. | Mylan Pharmaceuticals Inc. |
US5977089 | June, 2014 |
Terminated-Denied
(09 Dec, 2014)
| Gilead Sciences, Inc. | Mylan Pharmaceuticals Inc. |
US6043230 | June, 2014 |
Terminated-Denied
(09 Dec, 2014)
| Gilead Sciences, Inc. | Mylan Pharmaceuticals Inc. |
US8633219 | August, 2011 |
Decision
(19 Jul, 2012)
| Yuji Matsuzaki et al | |
US6703396 | April, 2002 |
Decision
(04 Apr, 2002)
| DIONNE | |
US6642245 | July, 2001 |
Decision
(05 Jul, 2001)
| DIONNE |
Gilead Sciences Inc Drug Patents' Oppositions Filed in EPO
Gilead Sciences Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Mar 13, 2009, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP04701819A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP16180589A | Oct, 2020 | Cooke, Richard | Granted and Under Opposition |
EP16180589A | Oct, 2020 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
EP16798063A | May, 2020 | Sandoz GmbH | Granted and Under Opposition |
EP16798063A | May, 2020 | Cooke, Richard | Granted and Under Opposition |
EP16798063A | May, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
EP16180589A | Jan, 2020 | STADA Arzneimittel AG | Granted and Under Opposition |
EP15739063A | Oct, 2018 | Cooke, Richard | Revoked |
EP12768967A | Aug, 2018 | Gillard, Richard Edward | Patent maintained as amended |
EP13164300A | Jan, 2018 | Georg Kalhammer/Stephan Teipel | Granted and Under Opposition |
EP13164300A | Jan, 2018 | Aechter, Bernd | Granted and Under Opposition |
EP13164300A | Jan, 2018 | Cooke, Richard | Granted and Under Opposition |
EP12753867A | Jul, 2017 | FRKelly | Granted and Under Opposition |
EP12753867A | Jul, 2017 | Sandoz GmbH | Granted and Under Opposition |
EP12753867A | Jul, 2017 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
EP05752122A | Jun, 2017 | STADA Arzneimittel AG | Opposition rejected |
EP12167590A | May, 2017 | Cooke, Richard | Revoked |
EP12167591A | May, 2017 | Cooke, Richard | Revoked |
EP12167590A | May, 2017 | Teva Pharmaceutical Industries LTD. | Revoked |
EP12167591A | May, 2017 | Teva Pharmaceutical Industries LTD. | Revoked |
EP12167589A | May, 2017 | Cooke, Richard | Granted and Under Opposition |
EP12167589A | May, 2017 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
EP12167596A | Apr, 2017 | Cooke, Richard | Revoked |
EP12167596A | Apr, 2017 | Teva Pharmaceutical Industries Ltd | Revoked |
EP09739981A | Jun, 2016 | Cooke, Richard | Revoked |
EP09739981A | Jun, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
EP10703766A | Apr, 2016 | Cooke, Richard | Revoked |
EP10703766A | Apr, 2016 | Teva Pharmaceutical Industries Ltd | Revoked |
EP07836007A | Mar, 2016 | Trösch, Dominique | Granted and Under Opposition |
EP07836007A | Mar, 2016 | Georg Kalhammer/Stephan Teipel | Granted and Under Opposition |
EP07836007A | Mar, 2016 | Teva Pharmaceutical Industries LTD. | Granted and Under Opposition |
EP04787096A | Jan, 2016 | Page White & Farrer Limited | Patent maintained as amended |
EP01961695A | Nov, 2015 | HEXAL PHARMA AG | Patent maintained as amended |
EP01961695A | Nov, 2015 | Strawman Limited | Patent maintained as amended |
EP01961695A | Nov, 2015 | Swindell & Pearson Limited | Patent maintained as amended |
EP01961695A | Nov, 2015 | Teva Pharmaceutical Industries Ltd | Patent maintained as amended |
EP11791161A | Jun, 2015 | HGF Limited | Patent maintained as amended |
EP11791161A | Jun, 2015 | LEK Pharmaceuticals d.d. | Patent maintained as amended |
EP08732818A | Feb, 2015 | Intellectual Property Services (IPS) | Granted and Under Opposition |
EP08732818A | Feb, 2015 | STADA Arzneimittel AG | Granted and Under Opposition |
EP08732818A | Feb, 2015 | Actavis Group PTC ehf | Granted and Under Opposition |
EP08732818A | Feb, 2015 | ZBM Patents - Zea, Barlocci & Markvardsen | Granted and Under Opposition |
EP08732818A | Feb, 2015 | Pharmaceutical Works POLPHARMA | Granted and Under Opposition |
EP08732818A | Feb, 2015 | Generics [UK] Ltd (trading as Mylan) | Granted and Under Opposition |
EP08732818A | Feb, 2015 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
EP08732818A | Feb, 2015 | Fleischer, Holm Herbert | Granted and Under Opposition |
EP08732818A | Feb, 2015 | ELLIS IP LTD | Granted and Under Opposition |
EP08732818A | Feb, 2015 | MEDECINS DU MONDE | Granted and Under Opposition |
EP05108086A | Feb, 2012 | Hamm, Volker | The patent has been limited |
EP04701819A | Mar, 2009 | Generics [UK] Limited | Revoked |
EP04701819A | Mar, 2009 | Teva Pharmaceutical Industries LTD. | Revoked |
Gilead Sciences Inc's Family Patents
Gilead Sciences Inc Drug List
Given below is the complete list of Gilead Sciences Inc's drugs and the patents protecting them.
1. Biktarvy
Biktarvy is protected by 15 patents, out of which 3 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10548846 | Therapeutic compositions for treatment of human immunodeficiency virus |
08 Nov, 2036
(12 years from now)
| Active |
US11744802 | Therapeutic compositions for treatment of human immunodeficiency virus |
08 Nov, 2036
(12 years from now)
| Active |
US10385067 | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate |
19 Jun, 2035
(10 years from now)
| Active |
US9708342 | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate |
19 Jun, 2035
(10 years from now)
| Active |
US9216996 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections |
19 Dec, 2033
(9 years from now)
| Active |
US9732092 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections |
19 Dec, 2033
(9 years from now)
| Active |
US8754065
(Pediatric)
| Tenofovir alafenamide hemifumarate |
15 Feb, 2033
(8 years from now)
| Active |
US9296769
(Pediatric)
| Tenofovir alafenamide hemifumarate |
15 Feb, 2033
(8 years from now)
| Active |
US8754065 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
US9296769 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
US7390791
(Pediatric)
| Prodrugs of phosphonate nucleotide analogues |
17 Oct, 2025
(1 year, 11 days from now)
| Active |
US7390791 | Prodrugs of phosphonate nucleotide analogues |
17 Apr, 2025
(6 months from now)
| Active |
US7803788 | Prodrugs of phosphonate nucoleotide analogues |
02 Feb, 2022
(2 years ago)
| Expired |
US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Mar, 2021
(3 years ago)
| Expired |
US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 Nov, 2020
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Biktarvy's drug page
2. Complera
Complera is protected by 28 patents, out of which 25 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10857102 | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
14 Jan, 2033
(8 years from now)
| Active |
US8841310 | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
09 Dec, 2025
(1 year, 2 months from now)
| Active |
US7125879 | HIV inhibiting pyrimidines derivatives |
21 Apr, 2025
(6 months from now)
| Active |
US8716264
(Pediatric)
| Compositions and methods for combination antiviral therapy |
13 Jul, 2024
(2 months ago)
| Expired |
US8592397 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(8 months ago)
| Expired |
US8716264 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(8 months ago)
| Expired |
US9457036 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(8 months ago)
| Expired |
US9744181 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(8 months ago)
| Expired |
US8080551 | HIV inhibiting pyrimidines derivatives |
11 Apr, 2023
(1 year, 5 months ago)
| Expired |
US8101629 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
09 Aug, 2022
(2 years ago)
| Expired |
US6703396
(Pediatric)
| Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Sep, 2021
(3 years ago)
| Expired |
US6642245
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 May, 2021
(3 years ago)
| Expired |
US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Mar, 2021
(3 years ago)
| Expired |
US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
26 Feb, 2021
(3 years ago)
| Expired |
US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 Nov, 2020
(3 years ago)
| Expired |
US7067522 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
20 Dec, 2019
(4 years ago)
| Expired |
US5922695
(Pediatric)
| Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
25 Jan, 2018
(6 years ago)
| Expired |
US5935946
(Pediatric)
| Nucleotide analog composition and synthesis method |
25 Jan, 2018
(6 years ago)
| Expired |
US5977089
(Pediatric)
| Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jan, 2018
(6 years ago)
| Expired |
US6043230
(Pediatric)
| Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jan, 2018
(6 years ago)
| Expired |
US5914331
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jan, 2018
(6 years ago)
| Expired |
US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
25 Jul, 2017
(7 years ago)
| Expired |
US5935946 | Nucleotide analog composition and synthesis method |
25 Jul, 2017
(7 years ago)
| Expired |
US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jul, 2017
(7 years ago)
| Expired |
US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jul, 2017
(7 years ago)
| Expired |
US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jul, 2017
(7 years ago)
| Expired |
US5814639
(Pediatric)
| Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Mar, 2016
(8 years ago)
| Expired |
US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Complera's drug page
3. Descovy
Descovy is protected by 15 patents, out of which 9 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8754065
(Pediatric)
| Tenofovir alafenamide hemifumarate |
15 Feb, 2033
(8 years from now)
| Active |
US9296769
(Pediatric)
| Tenofovir alafenamide hemifumarate |
15 Feb, 2033
(8 years from now)
| Active |
US8754065 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
US9296769 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
US7390791
(Pediatric)
| Prodrugs of phosphonate nucleotide analogues |
17 Oct, 2025
(1 year, 11 days from now)
| Active |
US7390791 | Prodrugs of phosphonate nucleotide analogues |
17 Apr, 2025
(6 months from now)
| Active |
US7803788 | Prodrugs of phosphonate nucoleotide analogues |
02 Feb, 2022
(2 years ago)
| Expired |
US6703396
(Pediatric)
| Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Sep, 2021
(3 years ago)
| Expired |
US6642245
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 May, 2021
(3 years ago)
| Expired |
US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Mar, 2021
(3 years ago)
| Expired |
US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 Nov, 2020
(3 years ago)
| Expired |
US5914331
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jan, 2018
(6 years ago)
| Expired |
US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jul, 2017
(7 years ago)
| Expired |
US5814639
(Pediatric)
| Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Mar, 2016
(8 years ago)
| Expired |
US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Descovy's drug page
4. Epclusa
Epclusa is protected by 32 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10086011
(Pediatric)
| Combination formulation of two antiviral compounds |
30 Jul, 2034
(9 years from now)
| Active |
US11116783
(Pediatric)
| Combination formulation of two antiviral compounds |
30 Jul, 2034
(9 years from now)
| Active |
US11707479
(Pediatric)
| Combination formulation of two antiviral compounds |
30 Jul, 2034
(9 years from now)
| Active |
US9757406
(Pediatric)
| Combination formulation of two antiviral compounds |
30 Jul, 2034
(9 years from now)
| Active |
US10086011 | Combination formulation of two antiviral compounds |
30 Jan, 2034
(9 years from now)
| Active |
US11116783 | Combination formulation of two antiviral compounds |
30 Jan, 2034
(9 years from now)
| Active |
US11707479 | Combination formulation of two antiviral compounds |
30 Jan, 2034
(9 years from now)
| Active |
US9757406 | Combination formulation of two antiviral compounds |
30 Jan, 2034
(9 years from now)
| Active |
US8575135
(Pediatric)
| Antiviral compounds |
16 May, 2033
(8 years from now)
| Active |
US8921341
(Pediatric)
| Antiviral compounds |
16 May, 2033
(8 years from now)
| Active |
US8940718
(Pediatric)
| Antiviral compounds |
16 May, 2033
(8 years from now)
| Active |
US8575135 | Antiviral compounds |
16 Nov, 2032
(8 years from now)
| Active |
US8921341 | Antiviral compounds |
16 Nov, 2032
(8 years from now)
| Active |
US8940718 | Antiviral compounds |
16 Nov, 2032
(8 years from now)
| Active |
US8618076
(Pediatric)
| Nucleoside phosphoramidates |
11 Jun, 2031
(6 years from now)
| Active |
US9284342
(Pediatric)
| Nucleoside phosphoramidates |
13 Mar, 2031
(6 years from now)
| Active |
US8618076 | Nucleoside phosphoramidates |
11 Dec, 2030
(6 years from now)
| Active |
US9284342 | Nucleoside phosphoramidates |
13 Sep, 2030
(5 years from now)
| Active |
US7964580
(Pediatric)
| NA |
26 Sep, 2029
(4 years from now)
| Active |
US8633309
(Pediatric)
| Nucleoside phosphoramidates |
26 Sep, 2029
(4 years from now)
| Active |
US8889159
(Pediatric)
| Compositions and methods for treating hepatitis C virus |
26 Sep, 2029
(4 years from now)
| Active |
US7964580 | NA |
26 Mar, 2029
(4 years from now)
| Active |
US8633309 | Nucleoside phosphoramidates |
26 Mar, 2029
(4 years from now)
| Active |
US8889159 | Compositions and methods for treating hepatitis C virus |
26 Mar, 2029
(4 years from now)
| Active |
US8334270
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8580765
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8735372
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US9085573
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8334270 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US8580765 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US8735372 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US9085573 | NA |
21 Mar, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epclusa's drug page
5. Genvoya
Genvoya is protected by 30 patents, out of which 10 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10039718
(Pediatric)
| Use of solid carrier particles to improve the processability of a pharmaceutical agent |
06 Apr, 2033
(8 years from now)
| Active |
US8754065
(Pediatric)
| Tenofovir alafenamide hemifumarate |
15 Feb, 2033
(8 years from now)
| Active |
US9296769
(Pediatric)
| Tenofovir alafenamide hemifumarate |
15 Feb, 2033
(8 years from now)
| Active |
US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
06 Oct, 2032
(8 years from now)
| Active |
US8754065 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
US9296769 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
US8633219
(Pediatric)
| Combination therapy |
30 Oct, 2030
(6 years from now)
| Active |
US8633219 | Combination therapy |
30 Apr, 2030
(5 years from now)
| Active |
US8148374
(Pediatric)
| Modulators of pharmacokinetic properties of therapeutics |
03 Mar, 2030
(5 years from now)
| Active |
US9891239
(Pediatric)
| Modulators of pharmacokinetic properties of therapeutics |
03 Mar, 2030
(5 years from now)
| Active |
US8148374 | Modulators of pharmacokinetic properties of therapeutics |
03 Sep, 2029
(4 years from now)
| Active |
US9891239 | Modulators of pharmacokinetic properties of therapeutics |
03 Sep, 2029
(4 years from now)
| Active |
US7635704
(Pediatric)
| Stable crystal of 4-oxoquinoline compound |
26 Apr, 2027
(2 years from now)
| Active |
US8981103
(Pediatric)
| Stable crystal of 4-oxoquinoline compound |
26 Apr, 2027
(2 years from now)
| Active |
US7176220
(Pediatric)
| 4-oxoquinoline compound and use thereof as pharmaceutical agent |
27 Feb, 2027
(2 years from now)
| Active |
US7635704 | Stable crystal of 4-oxoquinoline compound |
26 Oct, 2026
(2 years from now)
| Active |
US8981103 | Stable crystal of 4-oxoquinoline compound |
26 Oct, 2026
(2 years from now)
| Active |
US7176220 | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
27 Aug, 2026
(1 year, 10 months from now)
| Active |
US7390791
(Pediatric)
| Prodrugs of phosphonate nucleotide analogues |
17 Oct, 2025
(1 year, 11 days from now)
| Active |
US7390791 | Prodrugs of phosphonate nucleotide analogues |
17 Apr, 2025
(6 months from now)
| Active |
US7800788 | Upright image processing apparatus with pivotable image reading portion |
02 Feb, 2022
(2 years ago)
| Expired |
US7803788 | Prodrugs of phosphonate nucoleotide analogues |
02 Feb, 2022
(2 years ago)
| Expired |
US6703396
(Pediatric)
| Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Sep, 2021
(3 years ago)
| Expired |
US6642245
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 May, 2021
(3 years ago)
| Expired |
US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Mar, 2021
(3 years ago)
| Expired |
US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 Nov, 2020
(3 years ago)
| Expired |
US5914331
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jan, 2018
(6 years ago)
| Expired |
US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jul, 2017
(7 years ago)
| Expired |
US5814639
(Pediatric)
| Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Mar, 2016
(8 years ago)
| Expired |
US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Genvoya's drug page
Explore Our Curated Drug Screens
6. Harvoni
Harvoni is protected by 33 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10039779
(Pediatric)
| Combination formulation of two antiviral compounds |
30 Jul, 2034
(9 years from now)
| Active |
US10039779 | Combination formulation of two antiviral compounds |
30 Jan, 2034
(9 years from now)
| Active |
US9393256
(Pediatric)
| Methods for treating HCV |
14 Mar, 2033
(8 years from now)
| Active |
US10456414 | Methods for treating HCV |
14 Sep, 2032
(7 years from now)
| Active |
US9393256 | Methods for treating HCV |
14 Sep, 2032
(7 years from now)
| Active |
US8618076
(Pediatric)
| Nucleoside phosphoramidates |
11 Jun, 2031
(6 years from now)
| Active |
US9284342
(Pediatric)
| Nucleoside phosphoramidates |
13 Mar, 2031
(6 years from now)
| Active |
US8618076 | Nucleoside phosphoramidates |
11 Dec, 2030
(6 years from now)
| Active |
US8088368
(Pediatric)
| Antiviral compounds |
12 Nov, 2030
(6 years from now)
| Active |
US8273341
(Pediatric)
| Antiviral compounds |
12 Nov, 2030
(6 years from now)
| Active |
US8822430
(Pediatric)
| Antiviral compounds |
12 Nov, 2030
(6 years from now)
| Active |
US8841278
(Pediatric)
| Antiviral compounds |
12 Nov, 2030
(6 years from now)
| Active |
US9511056
(Pediatric)
| Antiviral compounds |
12 Nov, 2030
(6 years from now)
| Active |
US9284342 | Nucleoside phosphoramidates |
13 Sep, 2030
(5 years from now)
| Active |
US8088368 | Antiviral compounds |
12 May, 2030
(5 years from now)
| Active |
US8273341 | Antiviral compounds |
12 May, 2030
(5 years from now)
| Active |
US8822430 | Antiviral compounds |
12 May, 2030
(5 years from now)
| Active |
US8841278 | Antiviral compounds |
12 May, 2030
(5 years from now)
| Active |
US9511056 | Antiviral compounds |
12 May, 2030
(5 years from now)
| Active |
US7964580
(Pediatric)
| NA |
26 Sep, 2029
(4 years from now)
| Active |
US8633309
(Pediatric)
| Nucleoside phosphoramidates |
26 Sep, 2029
(4 years from now)
| Active |
US8889159
(Pediatric)
| Compositions and methods for treating hepatitis C virus |
26 Sep, 2029
(4 years from now)
| Active |
US7964580 | NA |
26 Mar, 2029
(4 years from now)
| Active |
US8633309 | Nucleoside phosphoramidates |
26 Mar, 2029
(4 years from now)
| Active |
US8889159 | Compositions and methods for treating hepatitis C virus |
26 Mar, 2029
(4 years from now)
| Active |
US8334270
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8580765
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8735372
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US9085573
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8334270 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US8580765 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US8735372 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US9085573 | NA |
21 Mar, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Harvoni's drug page
7. Odefsey
Odefsey is protected by 20 patents, out of which 13 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8754065
(Pediatric)
| Tenofovir alafenamide hemifumarate |
15 Feb, 2033
(8 years from now)
| Active |
US9296769
(Pediatric)
| Tenofovir alafenamide hemifumarate |
15 Feb, 2033
(8 years from now)
| Active |
US8754065 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
US9296769 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
US7390791
(Pediatric)
| Prodrugs of phosphonate nucleotide analogues |
17 Oct, 2025
(1 year, 11 days from now)
| Active |
US7125879 | HIV inhibiting pyrimidines derivatives |
21 Apr, 2025
(6 months from now)
| Active |
US7390791 | Prodrugs of phosphonate nucleotide analogues |
17 Apr, 2025
(6 months from now)
| Active |
US8080551 | HIV inhibiting pyrimidines derivatives |
11 Apr, 2023
(1 year, 5 months ago)
| Expired |
US8101629 | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
09 Aug, 2022
(2 years ago)
| Expired |
US7803788 | Prodrugs of phosphonate nucoleotide analogues |
02 Feb, 2022
(2 years ago)
| Expired |
US6703396
(Pediatric)
| Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Sep, 2021
(3 years ago)
| Expired |
US6642245
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 May, 2021
(3 years ago)
| Expired |
US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Mar, 2021
(3 years ago)
| Expired |
US6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
26 Feb, 2021
(3 years ago)
| Expired |
US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 Nov, 2020
(3 years ago)
| Expired |
US7067522 | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
20 Dec, 2019
(4 years ago)
| Expired |
US5914331
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jan, 2018
(6 years ago)
| Expired |
US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jul, 2017
(7 years ago)
| Expired |
US5814639
(Pediatric)
| Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Mar, 2016
(8 years ago)
| Expired |
US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Odefsey's drug page
8. Sovaldi
Sovaldi is protected by 18 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8618076
(Pediatric)
| Nucleoside phosphoramidates |
11 Jun, 2031
(6 years from now)
| Active |
US9284342
(Pediatric)
| Nucleoside phosphoramidates |
13 Mar, 2031
(6 years from now)
| Active |
US8618076 | Nucleoside phosphoramidates |
11 Dec, 2030
(6 years from now)
| Active |
US9284342 | Nucleoside phosphoramidates |
13 Sep, 2030
(5 years from now)
| Active |
US7964580
(Pediatric)
| NA |
26 Sep, 2029
(4 years from now)
| Active |
US8633309
(Pediatric)
| Nucleoside phosphoramidates |
26 Sep, 2029
(4 years from now)
| Active |
US8889159
(Pediatric)
| Compositions and methods for treating hepatitis C virus |
26 Sep, 2029
(4 years from now)
| Active |
US9549941
(Pediatric)
| Compositions and methods for treating hepatitis C virus |
26 Sep, 2029
(4 years from now)
| Active |
US7964580 | NA |
26 Mar, 2029
(4 years from now)
| Active |
US8633309 | Nucleoside phosphoramidates |
26 Mar, 2029
(4 years from now)
| Active |
US8889159 | Compositions and methods for treating hepatitis C virus |
26 Mar, 2029
(4 years from now)
| Active |
US9549941 | Compositions and methods for treating hepatitis C virus |
26 Mar, 2029
(4 years from now)
| Active |
US8334270
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8580765
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US9085573
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8334270 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US8580765 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US9085573 | NA |
21 Mar, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sovaldi's drug page
9. Stribild
Stribild is protected by 35 patents, out of which 21 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10039718
(Pediatric)
| Use of solid carrier particles to improve the processability of a pharmaceutical agent |
06 Apr, 2033
(8 years from now)
| Active |
US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
06 Oct, 2032
(8 years from now)
| Active |
US8633219
(Pediatric)
| Combination therapy |
30 Oct, 2030
(6 years from now)
| Active |
US8633219 | Combination therapy |
30 Apr, 2030
(5 years from now)
| Active |
US8148374
(Pediatric)
| Modulators of pharmacokinetic properties of therapeutics |
03 Mar, 2030
(5 years from now)
| Active |
US9891239
(Pediatric)
| Modulators of pharmacokinetic properties of therapeutics |
03 Mar, 2030
(5 years from now)
| Active |
US8148374 | Modulators of pharmacokinetic properties of therapeutics |
03 Sep, 2029
(4 years from now)
| Active |
US9891239 | Modulators of pharmacokinetic properties of therapeutics |
03 Sep, 2029
(4 years from now)
| Active |
US7635704
(Pediatric)
| Stable crystal of 4-oxoquinoline compound |
26 Apr, 2027
(2 years from now)
| Active |
US8981103
(Pediatric)
| Stable crystal of 4-oxoquinoline compound |
26 Apr, 2027
(2 years from now)
| Active |
US7176220
(Pediatric)
| 4-oxoquinoline compound and use thereof as pharmaceutical agent |
27 Feb, 2027
(2 years from now)
| Active |
US7635704 | Stable crystal of 4-oxoquinoline compound |
26 Oct, 2026
(2 years from now)
| Active |
US8981103 | Stable crystal of 4-oxoquinoline compound |
26 Oct, 2026
(2 years from now)
| Active |
US7176220 | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
27 Aug, 2026
(1 year, 10 months from now)
| Active |
US8716264
(Pediatric)
| Compositions and methods for combination antiviral therapy |
13 Jul, 2024
(2 months ago)
| Expired |
US8592397 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(8 months ago)
| Expired |
US8716264 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(8 months ago)
| Expired |
US9457036 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(8 months ago)
| Expired |
US9744181 | Compositions and methods for combination antiviral therapy |
13 Jan, 2024
(8 months ago)
| Expired |
US6703396
(Pediatric)
| Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Sep, 2021
(3 years ago)
| Expired |
US6642245
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 May, 2021
(3 years ago)
| Expired |
US6703396 | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
09 Mar, 2021
(3 years ago)
| Expired |
US6642245 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
04 Nov, 2020
(3 years ago)
| Expired |
US5922695
(Pediatric)
| Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
25 Jan, 2018
(6 years ago)
| Expired |
US5935946
(Pediatric)
| Nucleotide analog composition and synthesis method |
25 Jan, 2018
(6 years ago)
| Expired |
US5977089
(Pediatric)
| Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jan, 2018
(6 years ago)
| Expired |
US6043230
(Pediatric)
| Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jan, 2018
(6 years ago)
| Expired |
US5914331
(Pediatric)
| Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jan, 2018
(6 years ago)
| Expired |
US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
25 Jul, 2017
(7 years ago)
| Expired |
US5935946 | Nucleotide analog composition and synthesis method |
25 Jul, 2017
(7 years ago)
| Expired |
US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jul, 2017
(7 years ago)
| Expired |
US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jul, 2017
(7 years ago)
| Expired |
US5914331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
02 Jul, 2017
(7 years ago)
| Expired |
US5814639
(Pediatric)
| Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Mar, 2016
(8 years ago)
| Expired |
US5814639 | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
29 Sep, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stribild's drug page
10. Sunlenca
Sunlenca is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11944611 | Capsid inhibitors for the treatment of HIV |
04 Jun, 2041
(16 years from now)
| Active |
US11267799 | Solid forms of an HIV capsid inhibitor |
16 Aug, 2038
(13 years from now)
| Active |
US10071985 | Therapeutic compounds |
17 Aug, 2037
(12 years from now)
| Active |
US10654827 | Therapeutic compounds |
17 Aug, 2037
(12 years from now)
| Active |
US9951043 | Therapeutic compounds |
28 Feb, 2034
(9 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sunlenca's drug page
11. Tybost
Tybost is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US10039718
(Pediatric)
| Use of solid carrier particles to improve the processability of a pharmaceutical agent |
06 Apr, 2033
(8 years from now)
| Active |
US10039718 | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
06 Oct, 2032
(8 years from now)
| Active |
US8148374
(Pediatric)
| Modulators of pharmacokinetic properties of therapeutics |
03 Mar, 2030
(5 years from now)
| Active |
US8148374 | Modulators of pharmacokinetic properties of therapeutics |
03 Sep, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tybost's drug page
12. Veklury
Veklury is protected by 32 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11491169
(Pediatric)
| Remdesivir treatment methods |
28 Nov, 2041
(17 years from now)
| Active |
US11903953
(Pediatric)
| Remdesivir treatment methods |
28 Nov, 2041
(17 years from now)
| Active |
US11975012
(Pediatric)
| Remdesivir treatment methods |
28 Nov, 2041
(17 years from now)
| Active |
US11491169 | Remdesivir treatment methods |
28 May, 2041
(16 years from now)
| Active |
US11903953 | Remdesivir treatment methods |
28 May, 2041
(16 years from now)
| Active |
US11975012 | Remdesivir treatment methods |
28 May, 2041
(16 years from now)
| Active |
US10675296
(Pediatric)
| Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
10 Jan, 2039
(14 years from now)
| Active |
US11266681
(Pediatric)
| Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
10 Jan, 2039
(14 years from now)
| Active |
US11975017
(Pediatric)
| Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
10 Jan, 2039
(14 years from now)
| Active |
US10675296 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
10 Jul, 2038
(13 years from now)
| Active |
US11266681 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
10 Jul, 2038
(13 years from now)
| Active |
US11975017 | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
10 Jul, 2038
(13 years from now)
| Active |
US10695361
(Pediatric)
| Methods for treating arenaviridae and coronaviridae virus infections |
16 Mar, 2037
(12 years from now)
| Active |
US11007208
(Pediatric)
| Methods for treating arenaviridae and coronaviridae virus infections |
16 Mar, 2037
(12 years from now)
| Active |
US11382926
(Pediatric)
| Methods for treating Arenaviridae and Coronaviridae virus infections |
16 Mar, 2037
(12 years from now)
| Active |
US10695361 | Methods for treating arenaviridae and coronaviridae virus infections |
16 Sep, 2036
(11 years from now)
| Active |
US11007208 | Methods for treating arenaviridae and coronaviridae virus infections |
16 Sep, 2036
(11 years from now)
| Active |
US11382926 | Methods for treating Arenaviridae and Coronaviridae virus infections |
16 Sep, 2036
(11 years from now)
| Active |
US9724360
(Pediatric)
| Methods for treating Filoviridae virus infections |
29 Apr, 2036
(11 years from now)
| Active |
US9949994
(Pediatric)
| Methods for treating Filoviridae virus infections |
29 Apr, 2036
(11 years from now)
| Active |
US9724360 | Methods for treating Filoviridae virus infections |
29 Oct, 2035
(11 years from now)
| Active |
US9949994 | Methods for treating Filoviridae virus infections |
29 Oct, 2035
(11 years from now)
| Active |
US11492353
(Pediatric)
| Methods and compounds for treating Paramyxoviridae virus infections |
08 Jun, 2032
(7 years from now)
| Active |
US10065958
(Pediatric)
| Methods and compounds for treating Paramyxoviridae virus infections |
16 Mar, 2032
(7 years from now)
| Active |
US11492353 | Methods and compounds for treating Paramyxoviridae virus infections |
08 Dec, 2031
(7 years from now)
| Active |
US10065958 | Methods and compounds for treating Paramyxoviridae virus infections |
16 Sep, 2031
(6 years from now)
| Active |
US8008264
(Pediatric)
| 1′-substituted carba-nucleoside analogs for antiviral treatment |
06 Mar, 2030
(5 years from now)
| Active |
US8318682
(Pediatric)
| 1′substituted carba-nucleoside analogs for antiviral treatment |
22 Oct, 2029
(5 years from now)
| Active |
USRE46762
(Pediatric)
| 1′-substituted carba-nucleoside analogs for antiviral treatment |
22 Oct, 2029
(5 years from now)
| Active |
US8008264 | 1′-substituted carba-nucleoside analogs for antiviral treatment |
06 Sep, 2029
(4 years from now)
| Active |
US8318682 | 1′substituted carba-nucleoside analogs for antiviral treatment |
22 Apr, 2029
(4 years from now)
| Active |
USRE46762 | 1′-substituted carba-nucleoside analogs for antiviral treatment |
22 Apr, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veklury's drug page
13. Vemlidy
Vemlidy is protected by 7 patents, out of which 1 has expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8754065
(Pediatric)
| Tenofovir alafenamide hemifumarate |
15 Feb, 2033
(8 years from now)
| Active |
US9296769
(Pediatric)
| Tenofovir alafenamide hemifumarate |
15 Feb, 2033
(8 years from now)
| Active |
US8754065 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
US9296769 | Tenofovir alafenamide hemifumarate |
15 Aug, 2032
(7 years from now)
| Active |
US7390791
(Pediatric)
| Prodrugs of phosphonate nucleotide analogues |
17 Oct, 2025
(1 year, 11 days from now)
| Active |
US7390791 | Prodrugs of phosphonate nucleotide analogues |
17 Apr, 2025
(6 months from now)
| Active |
US7803788 | Prodrugs of phosphonate nucoleotide analogues |
02 Feb, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vemlidy's drug page
14. Viread
Viread is protected by 8 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US5922695
(Pediatric)
| Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
25 Jan, 2018
(6 years ago)
| Expired |
US5935946
(Pediatric)
| Nucleotide analog composition and synthesis method |
25 Jan, 2018
(6 years ago)
| Expired |
US5977089
(Pediatric)
| Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jan, 2018
(6 years ago)
| Expired |
US6043230
(Pediatric)
| Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jan, 2018
(6 years ago)
| Expired |
US5922695 | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
25 Jul, 2017
(7 years ago)
| Expired |
US5935946 | Nucleotide analog composition and synthesis method |
25 Jul, 2017
(7 years ago)
| Expired |
US5977089 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jul, 2017
(7 years ago)
| Expired |
US6043230 | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
25 Jul, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viread's drug page
15. Vitekta
Vitekta is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US7635704
(Pediatric)
| Stable crystal of 4-oxoquinoline compound |
26 Apr, 2027
(2 years from now)
| Active |
US8981103
(Pediatric)
| Stable crystal of 4-oxoquinoline compound |
26 Apr, 2027
(2 years from now)
| Active |
US7176220
(Pediatric)
| 4-oxoquinoline compound and use thereof as pharmaceutical agent |
27 Feb, 2027
(2 years from now)
| Active |
US7635704 | Stable crystal of 4-oxoquinoline compound |
26 Oct, 2026
(2 years from now)
| Active |
US8981103 | Stable crystal of 4-oxoquinoline compound |
26 Oct, 2026
(2 years from now)
| Active |
US7176220 | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
27 Aug, 2026
(1 year, 10 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vitekta's drug page
16. Vosevi
Vosevi is protected by 33 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US11338007
(Pediatric)
| Combination formulation of three antiviral compounds |
01 Dec, 2037
(13 years from now)
| Active |
US10912814 | Combination formulation of three antiviral compounds |
01 Jun, 2037
(12 years from now)
| Active |
US11338007 | Combination formulation of three antiviral compounds |
01 Jun, 2037
(12 years from now)
| Active |
US11116783
(Pediatric)
| Combination formulation of two antiviral compounds |
30 Jul, 2034
(9 years from now)
| Active |
US9296782 | Inhibitors of hepatitis C virus |
17 Jul, 2034
(9 years from now)
| Active |
US11116783 | Combination formulation of two antiviral compounds |
30 Jan, 2034
(9 years from now)
| Active |
US8575135
(Pediatric)
| Antiviral compounds |
16 May, 2033
(8 years from now)
| Active |
US8921341
(Pediatric)
| Antiviral compounds |
16 May, 2033
(8 years from now)
| Active |
US8940718
(Pediatric)
| Antiviral compounds |
16 May, 2033
(8 years from now)
| Active |
US8575135 | Antiviral compounds |
16 Nov, 2032
(8 years from now)
| Active |
US8921341 | Antiviral compounds |
16 Nov, 2032
(8 years from now)
| Active |
US8940718 | Antiviral compounds |
16 Nov, 2032
(8 years from now)
| Active |
US9868745 | Antiviral compounds |
16 Nov, 2032
(8 years from now)
| Active |
US8618076
(Pediatric)
| Nucleoside phosphoramidates |
11 Jun, 2031
(6 years from now)
| Active |
US9284342
(Pediatric)
| Nucleoside phosphoramidates |
13 Mar, 2031
(6 years from now)
| Active |
US8618076 | Nucleoside phosphoramidates |
11 Dec, 2030
(6 years from now)
| Active |
US9284342 | Nucleoside phosphoramidates |
13 Sep, 2030
(5 years from now)
| Active |
US7964580
(Pediatric)
| NA |
26 Sep, 2029
(4 years from now)
| Active |
US8633309
(Pediatric)
| Nucleoside phosphoramidates |
26 Sep, 2029
(4 years from now)
| Active |
US8889159
(Pediatric)
| Compositions and methods for treating hepatitis C virus |
26 Sep, 2029
(4 years from now)
| Active |
US7964580 | NA |
26 Mar, 2029
(4 years from now)
| Active |
US8633309 | Nucleoside phosphoramidates |
26 Mar, 2029
(4 years from now)
| Active |
US8889159 | Compositions and methods for treating hepatitis C virus |
26 Mar, 2029
(4 years from now)
| Active |
US8334270
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8580765
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8735372
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US9085573
(Pediatric)
| NA |
21 Sep, 2028
(3 years from now)
| Active |
US8334270 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US8580765 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US8735372 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US8957046 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US9085573 | NA |
21 Mar, 2028
(3 years from now)
| Active |
US9585906 | NA |
21 Mar, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vosevi's drug page
17. Zydelig
Zydelig is protected by 13 patents, out of which 5 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9469643 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
02 Sep, 2033
(8 years from now)
| Active |
US10730879 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
05 Mar, 2033
(8 years from now)
| Active |
US8865730 | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
05 Mar, 2033
(8 years from now)
| Active |
US9492449 | Therapies for hematologic malignancies |
11 Mar, 2030
(5 years from now)
| Active |
USRE44638 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
05 Aug, 2025
(9 months from now)
| Active |
USRE44599 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
21 Jul, 2025
(9 months from now)
| Active |
US8980901 | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
12 May, 2025
(7 months from now)
| Active |
US9149477 | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta |
12 May, 2025
(7 months from now)
| Active |
US6800620 | Inhibitors of human phosphatidylinositol 3-kinase delta |
24 Apr, 2021
(3 years ago)
| Expired |
US6949535 | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
24 Apr, 2021
(3 years ago)
| Expired |
US8138195 | Inhibitors of human phosphatidylinositol 3-kinase delta |
24 Apr, 2021
(3 years ago)
| Expired |
US8492389 | Inhibitors of human phosphatidylinositol 3-kinase delta |
24 Apr, 2021
(3 years ago)
| Expired |
US8637533 | Inhibitors of human phosphatidylinositol 3-kinase delta |
24 Apr, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zydelig's drug page